Arrowhead Pharmaceuticals vs Halozyme
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Arrowhead Pharmaceuticals and Halozyme side by side, using each oneβs latest annual report. Here is what stands out:
- Halozyme is the larger business, with $1.4B of revenue in fiscal 2025 against $829M for Arrowhead Pharmaceuticals, about 1.7 times as much.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 37.6%).
- Halozyme kept more of each dollar of sales as operating profit (33.6% operating margin, against 11.9%).
- Halozyme turned more of its sales into free cash flow (46.2% FCF margin, against 18.9%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Arrowhead Pharmaceuticals
ARWR
3/9
Revenue growth5-year growthNet debt / EBITDA
Halozyme
HALO
5/9
Operating marginNet marginFCF marginReturn on equityShare count change
Side by side
Best in the row
| Latest fiscal year | ARWR FY25 | HALO FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.5B | $15.6B |
| Revenue | $829M | $1.4B |
| Free cash flow | $157M | $645M |
| Net income | β$1.6M | $317M |
| Growth | ||
| Revenue growth | 23,258.2% | 37.6% |
| 5-year growth | 56.6% | 39.2% |
| Share count change | 11.7% | β4.3% |
| Profitability | ||
| Gross margin | β | 83.6% |
| Operating margin | 11.9% | 33.6% |
| Net margin | β0.2% | 22.7% |
| FCF margin | 18.9% | 46.2% |
| Return on capital | β | 19.2% |
| Return on equity | β0.5% | 153.6% |
| Balance sheet | ||
| Net debt | β$665M | $2.0B |
| Net debt / EBITDA | β5.5x | 4.2x |
| Dividends and buybacks | $0.0M | $342M |
| Valuation & quality | ||
| P/E | β | 37.5x |
| Piotroski F-score | 5 | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.